Gain Therapeutics to Present Parkinson's Posters
The biotech company will share two late-breaking posters at a Milan congress and a separate preclinical poster at Neuroscience 2026 in Washington.
Updated on Nov. 5, 2026 in Alzheimer’s
Gain Therapeutics, a clinical-stage biotechnology company listed on Nasdaq as GANX, will present two late-breaking posters at the 31st IAPRD World Congress on Parkinson's Disease in Milan, Italy, from November 11-14, 2026. The company also has a poster scheduled for Neuroscience 2026 in Washington, D.C., from November 14-18, 2026.
Why it matters
The posters cover the company's lead candidate rexaceract (GT-02287), which is in a Phase 1b trial for Parkinson's disease with or without a GBA1 mutation, and a preclinical GCase allosteric modulator, GT-04686. The presentations are a public update on early-stage data for a condition that remains without a disease-modifying treatment.
The company's rexaceract program is in a Phase 1b trial, and its poster titles reference an open-label extension and a preclinical GBA1 model. The source does not disclose efficacy numbers, so the clinical and preclinical results remain unreported.
The players
Gain Therapeutics
A clinical-stage biotechnology company listed on Nasdaq under the symbol GANX and based in Bethesda, Maryland, developing treatments for neurodegenerative diseases.
IAPRD World Congress on Parkinson's Disease
The international congress of the International Association of Parkinsonism and Related Disorders, a global forum where clinicians and researchers present Parkinson's disease findings.
The details
One IAPRD poster, presented in a guided poster tour on November 13, 2026, from 3:30 to 4:30 p.m. CET, covers an open-label extension of the Phase 1b rexaceract study. A second poster examines GT-04686 in a GBA1 Parkinson's model, and a Neuroscience 2026 poster on November 17 reports that the same compound reduces neuropathology and improves motor and non-motor function in a preclinical model.
Timeline
November 11-14, 2026: 31st IAPRD World Congress on Parkinson's Disease in Milan, Italy.
November 13, 2026, 3:30-4:30 p.m. CET: guided poster tour of the P9.8 late-breaker.
November 14-18, 2026: Neuroscience 2026 annual meeting in Washington, D.C.
November 17, 2026, 8:00-9:00 a.m. EST: presentation of Poster PSTR222.06 at Neuroscience 2026.
Research Context
The posters extend the GBA1-linked approach to Parkinson's disease, in which GCase enzyme activity is the therapeutic target, by advancing an allosteric GCase modulator into clinical evaluation. The work sits within a broader research program aimed at slowing neurodegeneration rather than only managing symptoms.
For people living with Parkinson's disease, these posters offer early signals about whether a GCase-targeting therapy could eventually be an option, but no treatment is available from these data today. The results are early and do not yet change how the condition is managed.
The takeaway
Early-stage posters signal ongoing progress in GBA1-linked Parkinson's research, but readers should watch for peer-reviewed efficacy data before drawing conclusions about treatment potential.
What happens next
The IAPRD World Congress poster tour takes place November 13, 2026, and the Neuroscience 2026 poster presentation is scheduled for November 17, 2026.
Further reading
Explore more on Alzheimer's research and neurodegenerative disease coverage.
Source note: This article includes information reported by The Manila times.
